10 Bulk RNA-sequencing of hypothalamic nuclei comparing GLP-1MK-801 and semaglutide treatments
Clinical Update 3/02/2026 GLP-1 Supplement Caution A dangerous immune reaction was reported with a "GLP-1" supplement
A patient may be a candidate for GLP-1 weight loss if they have obesity, overweight with weight-related health concerns, insulin resistance, prediabetes, type 2 diabetes risk, high blood pressure, high cholesterol, fatty liver concerns, sleep apnea risk, or repeated difficulty losing and maintaining weight with lifestyle changes alone
Fifty-four percent of adults think its a good idea to use weight loss drugs such as Ozempic, Wegovy, Mounjaro, or Zepbound for adults with obesity or a weight related condition
A phased rollout is expected to extend eligibility progressively through June 2026 and March 2027